ClinicalTrials.gg
RecruitingNCT07521475EVOLVEUpdated Aug 3, 2026

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

An interventional study of Device: Omnipod M System with study CGM and Standard Therapy plus study CGM in Type 2 Diabetes Mellitus, sponsored by Insulet Corporation. Recruiting at 27 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Insulet Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
653rd of 2,960
350 · median 90
Started
2026
with 156 others
No phase
1,241 of 3,307
199 open now
Primary completion
2026-12
later than 146 of 477 live
Registered
3,217th of 3,307
by date

Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 653rd largest by planned enrollment of the 2,960 interventional ones that give a count, is one of 157 that started in 2026, is one of 1,241 with no phase, reaches primary completion later than 146 of the 477 other live ones, and was the 3,217th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Automated Insulin Delivery
  • T2D
  • Type 2 Diabetes
  • Omnipod
  • AID
  • Fully closed loop
  • FCL
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at time of consent 18-75 years (inclusive)
  2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening
  3. On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection.

    • Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin).
    • Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump
    • Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group
  4. For basal only users, screening ≥7.5% and \<14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and \<14.0%.

    • A1C measurement within 28 days prior to enrollment is acceptable
  5. Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic/biosimilar equivalents
  6. Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor
  7. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
  8. No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase)
  9. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety).
  10. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
  11. Willing to wear the system, including Pods, continuously throughout the 26-week trial phase
  12. Willing and able to sign the Form (ICF)
  13. Able to read and understand English
  14. If of , willing and able to have pregnancy testing

Exclusion criteria

Exclusion Criteria:

  1. Use of an automated insulin delivery pump within 3 months prior to screening
  2. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated , unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.
  3. Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
  4. Any planned surgery during the study which could be considered major in the opinion of the Investigator
  5. History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
  6. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
  7. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
  8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of
  9. Plans to receive blood transfusion over the course of the 26-week trial phase.
  10. Pregnant or lactating, or is of and not using an acceptable form of (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months ).
  11. Has taken systemic (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase.
  12. Participation in another clinical study using an drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase
  13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
  14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Intervention group - Omnipod M

    The Intervention group will be assigned the Omnipod M system with the study CGM

    Device: Device: Omnipod M System with study CGM

  • Active comparator
    Control group - Pre-study insulin regimen

    The control group will continue the use of pre-study insulin regimen with the study CGM.

    Device: Standard Therapy plus study CGM

Interventions

  • DeviceDevice: Omnipod M System with study CGM

    The Omnipod M system with the study CGM

    Also known as: Omnipod M System

  • DeviceStandard Therapy plus study CGM

    Standard therapy is continuation of pre-study insulin regimen and study CGM.

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. HbA1c

    Change in HbA1c (%) from baseline between the intervention and control groups

    Time frame: 15 and 26 weeks

Secondary outcomes

  1. Mean glucose

    Change in mean CGM glucose mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  2. Time in Range 70-180 mg/dL

    Change in CGM percent time 70-180 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  3. Time > 180 mg/dL

    Change in CGM percent time \>180 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  4. Time > 250 mg/dL

    Change in CGM percent time \>250 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  5. Time in Range 70-140 mg/dL

    Change in CGM percent time 70-140 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  6. Prolonged hyperglycemia events per week

    Change in number of prolonged hyperglycemia events (\>90 minutes with a CGM glucose \>250 mg/dL within a 120 minute period) from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  7. Time <70 mg/dL

    Change in CGM percent time \<70 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  8. Time <54 mg/dL

    Change in CGM percent time \<54 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  9. Time >300 mg/dL

    Change in CGM percent time \>300 mg/dL from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  10. Type 2 Diabetes Distress Assessment System (T2-DDAS)

    Time frame: 15 and 26 weeks

  11. Standard Deviation

    Change in standard deviation from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

Other outcomes

  1. Total daily insulin (TDI) and TDI/kg

    Change in TDI and TDI/kg from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  2. Percentage of insulin delivered via autobolus

    Change in percentage of insulin delivered via autobolus from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  3. Weight and body mass index

    Change in weight and body mass index from baseline, compared between the intervention and control groups

    Time frame: 15 and 26 weeks

  4. Patient reported outcome surveys

    Time frame: 15 and 26 weeks

  5. Additional HbA1c and CGM endpoints

    Time frame: 15 and 26 weeks

07

Study locations

26 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 7 months is below that.

Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 13, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Dec 24, 2026
CompletionEst.
Sep 23, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07521475
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 30, 2026
Primary completion
Dec 24, 2026 (estimated)
Completion
Sep 23, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Trang Ly, MBBS, PhD
Contact
APClinical@insulet.com
978-600-7000
Bonnie Dumais, RN
Contact
APClinical@insulet.com
978-600-7000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion